Abstract

Histoplasma duboisii, a variant of Histoplasma capsulatum that causes “African histoplasmosis,” can be resistant to itraconazole, requiring intravenous amphotericin B treatment. Rarely, these patients do not respond to intravenous antifungal therapy, and in such cases, patients may progress to develop secondary hemophagocytic lymphohistiocytosis (HLH). We present a case of a 34-year-old male patient with sickle cell disease who presented with a 5-month history of an enlarging painless axillary mass, persistent low grade fevers, night sweats, weight loss, and anorexia. An excisional biopsy of the right axillary lymph node revealed yeast and granulomas consistent with histoplasma infection. He was started on oral itraconazole. After 4 weeks of therapy, laboratory evaluation revealed worsening anemia, thrombocytopenia, and transaminitis. Due to failure of oral therapy, he was admitted for intravenous amphotericin B treatment. During his hospital course anemia, thrombocytopenia, and transaminitis all worsened. A bone marrow biopsy was done that was consistent with HLH. His clinical status continued to deteriorate, developing multiorgan failure and disseminated intravascular coagulation. He unfortunately had a cardiorespiratory arrest after eight days of admission and passed away.

Highlights

  • Disseminated histoplasmosis (DH) is a chronic granulomatous disease caused by Histoplasma capsulatum, usually in immunocompromised patients

  • DH is a chronic granulomatous disease caused by the dimorphic fungus Histoplasma capsulatum (HC)

  • DH is more common in immunocompromised populations and can be complicated by atypical presentation such as hemophagocytic lymphohistiocytosis (HLH)

Read more

Summary

Introduction

Disseminated histoplasmosis (DH) is a chronic granulomatous disease caused by Histoplasma capsulatum, usually in immunocompromised patients. Histoplasma duboisii, a variant of Histoplasma capsulatum that causes “African histoplasmosis,” is endemic to tropical and temperate areas of sub-Saharan Western Africa and Madagascar and can be resistant to itraconazole, requiring intravenous amphotericin B treatment [3]. These patients do not respond to intravenous antifungal therapy and in such cases, patients may progress to develop secondary hemophagocytic lymphohistiocytosis (HLH) [4, 5]. HLH is associated with a high mortality; early recognition and initiation of treatment is crucial

Case Presentation
Discussion
59 Negative Negative Negative
Findings
Conclusions
Conflict of Interests
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call